Programme Book - European Association of...

Gene

ral

EMUC17 • 16-19 November 2017, Barcelona, Spain 1

General Information

9th European Multidisciplinary Meeting on Urological Cancers

In conjunction with the

• 6th Meeting of the EAU Section of Urological Imaging (ESUI)

• EAU Prostate Cancer Centre Consensus Meeting (EPCCCM)

• EMUC Symposium on Genitourinary Pathology and

Molecular Diagnostics (ESUP)

• European School of Urology (ESU)

www.emuc17.org

Implementing multidisciplinary strategies in genito-urinary cancers

16-19 November 2017, Barcelona, Spain

Programme Book

ESUI176th Meeting of the EAU Section of Urological Imaging

webcastsSelected webcasts will be available shortly after the sessions

www.emuc17.org

ESUI17


Table of contents

Welcome 5Organising Committee 7

General 9Programme Overview 10Venue Floor Plan 12General Information 14About the Organisers 18

Scientific Programme 27Thursday, 16 November 28Friday, 17 November 38Saturday, 18 November 42Sunday, 19 November 47Hands-on Training (HOT) Courses 49

Faculty List 53

Continuing Medical Education (CME) Accreditation 55

Industry 57Industry Sessions 58Exhibition Floor Plan 62Exhibition: Company Profiles 66Acknowledgement Industry Partners 72

Download the EMUC17 appInstant access to all meeting info for ESUI17 and EMUC17

ESUI17

Download the ESUI17/ EMUC17 app and use your mobile device to vote during EMUC!

www.emuc17.org

Do not miss it and

join the voting sessions!

Voting

16-19 November 2017

Barcelona, Spain

EMUC2017


Welcome

Dear Colleagues,

Barcelona, Spain, is hosting the 9th European Multidisciplinary Meeting on Urological Cancers (EMUC17), one of Europe’s well-attended international conferences for multidisciplinary specialists with expertise in urological malignancies.

EMUC17 pursues the goals of earlier editions where critical insights on current and prospective treatment strategies will be discussed by leading experts and opinion leaders with special focus on best practices, achieving consensus on controversial issues and applying the outcomes of translational research.

Organisers of the EMUC draw from the collaborative efforts and resources of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Association of Urology (EAU). The collaboration not only offers an annual platform for scientific discussions that address emerging trends in urological cancers, but also links up various specialists and stakeholders in their common aim to achieve quality healthcare.

Affiliated organisations such as the European School of Urology (ESU) with ESU courses on Renal and Bladder Cancer and the EAU Section of Urological Imaging (ESUI) provide vital support to the event and widen the coverage of the Scientific Programme. Additionally, the EAU Prostate Cancer Centre Consensus Meeting (EPCCCM) are held to define the criteria for a European Prostate Cancer Centre.

From identifying forward-thinking approaches, discussing gaps in current treatment to improving standard medical protocols, the EMUC strives to achieve efficient multidisciplinary collaboration. After nearly a decade, participants of previous EMUC events have lauded EMUC’s role in anticipating key developments which enable cancer experts to tackle future challenges.

Welcome in Barcelona for another quality scientific exchange!

Dr. Thomas Powles, Prof. Peter Hoskin, Prof. Hein Van Poppel, London (GB), ESMO Northwood (GB), ESTRO Leuven (BE), EAU

6 EMUC17 • 16-19 November 2017, Barcelona, Spain

esmo.org

ESMO 2018

Save the date!

MUNICH GERMANY19-23 OCTOBER 2018

IMPORTANT DEADLINES

9 May 2018 Abstract submission

18 July 2018 Early registration

12 September 2018 Late registration

17 September 2018 Late-breaking abstracts


EMUC 2017 Organising Steering CommitteeESMO Prof. Thomas Powles, London (GB)ESTRO Prof. Peter Hoskin, Northwood (GB)EAU Prof. Hein Van Poppel, Leuven (BE)

EMUC 2017 Scientific CommitteeESMO Dr. Laurence Albiges, Villejuif (FR)ESMO Prof. Manuela Schmidinger, Vienna (AT) ESMO Dr. Jan Oldenburg, Oslo (NO) ESTRO Dr. Anne Kiltie, Oxford (GB)ESTRO Dr. Bradley Pieters, Amsterdam (NL)EAU Prof. Alberto Briganti, Milan (IT) EAU Prof. George Thalmann, Berne (CH) EORTC GUCG Prof. Silke Gillessen, St. Gallen (CH) EUOG Prof. Igle-Jan De Jong, Groningen (NL)ESUR Prof. Raymond Oyen, Leuven (BE) ESUR Prof. Harriet Thoeny, Berne (CH) ESUR Prof. Kerstin Junker, Homburg (DE)ESUP Prof. Rodolfo Montironi, Ancona (IT) ESOU Dr. Michiel Sedelaar, Nijmegen (NL)ESUI Prof. Georg Salomon, Hamburg (DE) YAU Dr. Evanguelos Xylinas, Paris (FR)

EMUC Congress OfficeCongress Consultants B.V.PO Box 300166803 AA ArnhemThe NetherlandsT +31 (0)26 389 1751F +31 (0)26 389 [email protected]

esmo.org

ESMO 2018

Save the date!

MUNICH GERMANY19-23 OCTOBER 2018

IMPORTANT DEADLINES

9 May 2018 Abstract submission

18 July 2018 Early registration

12 September 2018 Late registration

17 September 2018 Late-breaking abstracts

Organising Committee

WWW.ESTRO.ORG#ESTRO37

Early registration:17 January 2018

20-24 April 2018Barcelona, Spain

Innovation for Value

and Access

WWW.ESTRO.ORG#ESTRO37

Early registration:17 January 2018

20-24 April 2018Barcelona, Spain

Innovation for Value

and Access

General Information

Prog

ram

me

Over

view


Programme Overview

Thursday, 16 NovemberRoom H1, Level -1 Room H2, Level -1 Room E123, Level -1 Room A, Level -1

08.30 - 18.206th Meeting on the EAU

Section of Urological Imaging (ESUI)

09.00 - 12.30 ESU Course:

Interactive discussion on clinical scenarios in the management of localized, advanced

and metastatic kidney cancer

09.00 - 16.00EAU Prostate Cancer

Centre Consensus Meeting (EPCCCM)

13.00 - 16.00 ESU Course on Bladder

cancer: A practical approach

14.30 - 17.30 Symposium on Genito-Urinary Pathology and Molecular Diagnostics

(ESUP)

Friday, 17 NovemberAuditorium, Level 0 Room E456, Level -1 Room B123, Level -1 Room A, Level -1

08.15 - 17.459th European Multi-disciplinary Meeting

on Urological Cancers (EMUC17)

09.15 - 10.45ESU/ERUS Hands-on Training courses in

Robotic surgery

11.00 - 13.00ESU/ESUT/ESUI Hands-

on Training in MRI Fusion biopsy

09.30 - 12.30ESU/ESUT/ESUI MRI-course for

urologists in the diagnosis and

management of prostate cancer


Robotic surgery


Robotic surgery

14.00 - 16.00ESU/ESUT/ESUI Hands-

on Training in MRI Fusion biopsy

13.30 - 16.30ESU/ESUT/ESUI MRI-course for

urologists in the diagnosis and

management of prostate cancer15.30 - 17.15

ESU/ERUS Hands-on Training courses in

Robotic surgery

Prog

ram

me

Over

view


Programme Overview

Saturday, 18 NovemberAuditorium, Level 0 Room E456, Level -1 Room E123, Level -1

08.15 - 17.459th European Multidisciplinary Meeting on Urological Cancers

(EMUC17)

09.30 - 11.00ESU/ERUS Hands-on Training

courses in Robotic surgery

08.45 - 10.15FALCON contouring Workshop







17.45 - 18.45Uropathology training

workshop for clinicians

Sunday, 19 NovemberAuditorium, Level 0

08.45 - 12.309th European Multidisciplinary Meeting on Urological Cancers (EMUC17)

Floor Plan


Floo

r Pla

n

2

1

3

4

5

Floor Plan

H1H2

K1K2

K3 K4

AB123

E123E456

Level 0

Level -1


Floo

r Pla

n

2

1

3

4

5

H1H2

K1K2

K3 K4

AB123

E123E456

Pressroom 1

Pressroom 2

Level 1

Level 01 Auditorium2 Main Entrance3 Registration Area4 Exhibition & catering Area5 Poster Area

Level 1Pressroom 1 Meeting RoomPressroom 2 Speaker Service Centre Press Centre

Level -1H1 ESUIH2 ESUK1 Meeting RoomK2 Meeting RoomK3 Meeting RoomK4 Prayer RoomA ESUP HOT MRI ReadingB123 HOT MRI FusionE123 Falcon Workshop Uropathology Workshop EPCCCME456 HOT Robotic Surgery

Gene

ral


General Information

You can easily browse through scientific programmes with its user-friendly interface. Filter your search by day, session type, and speaker. You can even create your own personal programme with the personal planner feature!

The EMUC17 and ESUI17 App doesn’t necessarily require internet access. You can use the App offline but please note that some features will only be updated when you’re online e.g. news, tweets, etc. Discover the App´s many handy features. Download the App from the App store (iOS) or the Play store (Android).

CateringCoffee breaks and lunches will take place in the exhibition area.

Certificate of AttendanceA Certificate of Attendance can be printed online as of Monday, 20 November on www.emuc17.org and www.esui17.org. Before obtaining your Certificate of Attendance, you will be requested to enter the number under the barcode on your badge to log in (type the number without the *) as well as complete the evaluation questionnaire. It is therefore important to retain the delegate badge for this purpose.

Cloakroom/LuggageA cloakroom is located close to the registration area and is at participant’s disposal during meeting hours. Be sure to collect all your personal belongings at the end of the day.

ESUI17

DisclaimerDuring the 9th European MultidisciplinaryMeeting on Urological Cancers, the “Exhibition Booths related to prescription-only medicines” are only accessible to certified healthcare professionals, qualified to prescribe medicines, and pharmacists. Based on information provided by the registering party, the EMUC Congress office will indicate on the congress badges if the bearer has accreditation to access the “Exhibition Booths related to prescription-only medicines.” The accredited delegates will have the letter “P” on their badges. It is the responsibility of the registering party to provide correct information and the EMUC Congress office holds no responsibility with regards to the information provided. This measure is in accordance with the national and international pharmaceutical guidelines.

Abstracts and PostersThe EMUC17 and ESUI17 abstracts and posters are available online on www.emuc17.org and also in the App.

Address Congress Venue Palau de Congressos de CatalunyaAvda. Diagonal, 661-671 08028 Barcelona, Spainwww.fairmont.com/barcelonawww.pcongresos.com

AppOptimise your experience during the congress via the ESUI17/EMUC17 App. No lugging around printed materials nor painstakingly search for the info you need. Go digital and download this eco-friendly alternative!

Gene

ral


General Information

Congress BagEach delegate can collect a congress bag in the registration area.

Disclosure links to IndustryIt is requested that all faculty disclose to the audience any links with the industry related to the topic of their lecture at the beginning of each presentation. A link can be: Being a member of the advisory board or having a consulting agreement with a specific company.

Emergency InformationThe emergency phone number for police, fire brigade and ambulance service is 112. In case of an emergency in the congress venue contact the security or the organisation immediately. You can also reach the local police by calling 092, the local fire brigade via 080 and for accidents you can call 061.

ElectricityElectricity supply in Barcelona is 220 Volts and the connection is made by a two-pin plug. Please be aware that delegates from the USA will require a voltage converter. Delegates from the United Kingdom will require a plug adapter.

ExhibitionAn exhibition will be held jointly with the meeting. See page 66 for more information and profiles of the exhibiting companies.Opening hours:Thursday, 16 November 10.00 - 17.00 hrs. Friday, 17 November 09.00 - 17.00 hrs.Saturday, 18 November 09.00 - 17.00 hrs.

InsuranceThe organisers do not accept responsibility for any personal damage. Participants are strongly recommended to arrange their own personal insurance.

LanguageAll presentations during the meeting are conducted in English. No translation will be provided.

Lost and FoundFound items should be returned to the registration desk. If you lose or find something, please report to this desk for assistance.

Mobile Phones During all sessions, please switch your phone to silent and turn off your flash when taking pictures.

Poster Print Service Poster presenters who created their posters for EMUC17 and ESUI17 through the “PosterSessionOnline” printing & delivery service, can collect their poster at the faculty desk, located in the registration area.

Prayer RoomA special room dedicated to prayer is located in Room K4 on level -1.

Press Journalists can obtain free registration to the meeting. All media operators must show their credentials (press card dated 2017/2018 and original assignment letter).

Gene

ral


General Information

Registration AreaThe registration area is located on level 0 of the congress centre. Opening hours:Wednesday, 15 November 16.00 - 18.30 hrs.Thursday, 16 November 07.30 - 18.00 hrs.Friday, 17 November 07.00 - 19.00 hrs.Saturday, 18 November 07.30 - 18.00 hrs.Sunday, 19 November 08.00 - 13.00 hrs.

Registration Costs Satellite ProgrammeESUI17combined with EMUC €67,55 members €246,85non members €277,70ESU Coursesmembers €67,55non members €98,25ESUP €61,41ESU HOT Courses

Junior members, medical student members/ non member residents, medical students, PhD researchers & Nurses

€31,46

Registration Costs incl. VAT. For other prices and discounts, please go to the registration desk.

Security and SafetyThe safety of all congress attendees is of utmost importance to the EMUC Congress Office.Palau de Congressos and the organisers have taken security precautions to ensure the maximum possible safety for all EMUC17 participants. All bags may be subject to inspection. Please take all personal effects with you when leaving a session room.

Scientific PostersThe scientific posters are displayed on 16-19 November in the Poster Area, located in the exhibition. Members of the EMUC Scientific Committee will visit the EMUC poster area to discuss the posters with the presenters according to the following schedule:

Friday, 17 November 201710.50 - 11.20 Topics: Localised Prostate

Cancer, P001-P044 12.45 - 14.00 Topics: Advanced Prostate

Cancer, P045-P064 15.30 - 16.00 Topics: Prostate cancer,

P065-P088 Saturday, 18 November 2017 10.15 - 10.45 Topics: Renal Cell Carcinoma,

P089-P123 12.45 - 14.00 Topics: Bladder Cancer,

P124-P16116.05 - 16.35 Topics: Testicular & Penile,

P162-172

For those who present their poster on Friday you are kindly invited to attend the scientific programme on Saturday when we will announce the best poster at 08.15 hrs, in the main auditorium. For those who present their poster on Saturday you are kindly invited to attend the scientific programme on Sunday. The best poster will be announced at 08.30 hrs in the main auditorium.

Smoking PolicyThe EMUC Congress and the concomitant exhibition have been designated as non-smoking events throughout the entire venue, including all meeting halls, functions,

Gene

ral


General Information

registration and catering areas. All participants are kindly requested to respect the no-smoking policy, which also applies to e-cigarettes.

Social MediaThe use of social media is encouraged to create an open discussion on urology science and experiences at the congress. You are invited to use the hashtag #EMUC17 on Twitter and Facebook to discuss the congress, and join the conversation!

Speaker Service Centre (SSC)All presentations should be handed in at the Speaker Service Centre (located in Room Prensa II, level 1), at least three hours prior to the start of the session. Opening hours:Wednesday, 15 November 16.00 - 18.30 hrs.Thursday, 16 November 07.30 - 18.00 hrs.Friday, 17 November 07.00 - 19.00 hrs.Saturday, 18 November 08.00 - 18.00 hrs.Sunday, 19 November 08.00 - 12.30 hrs.

TransportationDelegates can collect a complimentary transportation pass in the registration area. The transportation pass is valid during 4 days and can be used for unlimited travel in busses, subways and trams within the city of Barcelona during the meeting.

Tourist InformationFor information about Barcelona, you can go to the Barcelona Info desk, or visit www.barcelonaturisme.com/en to find additional information.

VotingEMUC17 will include interactive voting. Download the ESUI17/EMUC17 App and use your mobile device to vote during EMUC. Do not miss it, and join the voting sessions!

WebcastsAll sessions during EMUC17 in Barcelona will be webcasted via www.emuc17.org, under the condition that the speaker has given his or her approval.

Wi-FiFree wireless internet will be available in all areas and session rooms. Please search for the “EMUC17” network and connect by entering the following password: EMUC2017

Abou

t


About the Organisers

The European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology, with the overarching goal of improving outcomes for cancer patients everywhere. We are the society of reference for oncology education and information, and are committed to supporting our members to develop and advance in a fast-evolving professional environment.

Founded in 1975, ESMO has European roots with a global reach: we welcome oncology professionals from around the world. We are a home for all oncology stakeholders, connecting professionals with diverse expertise and experience, and speaking with one voice for our discipline. Our education and information resources support an integrated multi-professional approach to cancer care, from a medical oncology perspective. We seek to erase boundaries in cancer care, whether between countries or specialities, and pursue our mission across oncology, worldwide.

The ESMO community brings together about 17,000 oncology professionals from over 150 countries. Drawing on 40 years of experience and around 500 expert committee members, ESMO serves its members and the oncology community through:

• Post-graduate oncology education and training• Career development and leadership training for the next generations of oncologists• International congresses and workshops to share expertise and best practice, learn

about the most up-to-date scientific advances, and connect with colleagues in related disciplines worldwide.

• Continuously reviewed, evidence-based standards for cancer care in Europe• Advocacy and consultation to foster a favourable environment for scientific research

ESMO Faculty offers a full range of post-graduate oncology education, along with online information resources and scientific journals. We foster the next generation of oncologists by providing career development and leadership training programmes. Our leading experts develop guidelines to define best clinical practice and support optimal care for cancer patients across Europe. We establish joint projects with cancer organisations to support closer integration of research, diagnostic, and clinical expertise. We speak for oncology in consultation with national, European, and international authorities, advocating for excellence in cancer research, evidence-based decision-making, and equal access to optimal care for patients. We bring together oncology professionals at international congresses and courses to share expertise and make new contacts.

Abou

t


As a globally growing society, ESMO gives oncology professionals worldwide a solid platform to support optimal care for their patients. Cancer care is rapidly becoming more integrated and more specialised; whether their field is research, diagnosis, treatment, care, or advocacy, professionals need to both build their specialist knowledge and connect with the best practitioners in other disciplines worldwide. ESMO membership makes this possible.

Please visit www.esmo.org to learn more. Across Oncology. Worldwide.

Abou

t



The European SocieTy for Radiotherapy and Oncology (ESTRO)

Founded in 1980, the European Society for Radiotherapy and Oncology, ESTRO, is a non-profit, scientific organisation whose role is to foster radiation oncology within a multidisciplinary setting and advocate for the best tailored treatment for cancer patients.

“Every cancer patient in Europe will have access to state of the art radiation therapy as part of a multidisciplinary approach where treatment is individualised for the specific patient’s cancer, taking account of the patient’s personal circumstances” - ESTRO Vision 2020 –

To fulfill the purpose of its mission, ESTRO supports the professional of the radiation oncology community in:• Developing and promoting standards of education and practice in radiotherapy and

clinical oncology• Disseminating and stimulating the exchange of scientific knowledge • Encouraging co-operation with international, regional and national societies and bodies

representing radiotherapy, clinical oncology and related subjects• Facilitating research and development in radiotherapy and other oncology related

subjects.• Developing public affairs activities.

2018 ESTRO membershipJoin a community of 7,000 oncology professionals and become an ESTRO member. ESTRO membership offers you exclusive benefits and services: • Online subscription to Radiotherapy & Oncology, • Discount on the article publication fee related to the new open access journals: Clinical

& Translational Oncology (ctRO), Physics & Imaging in Radiation Oncology (phiRO) and Technical Innovations & Patient Support in Radiation Oncology (tipsRO)

• Networking opportunities and reduced fees for attending ESTRO conferences, teaching courses and joint events

• Online access to scientific material (events webcasts, delineation cases, etc) through the e-library (DOVE)

• Eligibility for grants and awards• Eligibility for ESTRO faculties and governance positions

Register now for the 2018 ESTRO membership on www.estro.org/members.

Abou

t


2018 ESTRO meetings not to be missed

ESTRO 3720-24 April 2017 / Barcelona, Spain

The ESTRO annual congress is Europe’s most important congress for the radiation oncology community, with 6,000 participants attending each year. ESTRO 37 in 2018 will present new research results in radiation oncology through teaching lectures, symposia, debates and proffered papers. The congress also features a 10,000 sqm industrial exhibition.

6th GEC-ESTRO Workshop29-30 November 2018 / Brussels, Belgium

The GEC-ESTRO workshop is now a renowned hallmark event for networking within the brachytherapy community in Europe. It is an opportunity not to be missed. Come and learn as well as contribute to discussions on ongoing projects of the seven GEC-ESTRO working groups. ESTRO School

The ESTRO School is recognised internationally to provide high-quality education in multidisciplinary oncology and offers a wide range of activities:

- Live teaching courses: in 2018, 35 courses will be organised mostly in Europe and beyond that will attract 3,000 participants.

- e-learning tools have been developed in order to extend and coordinate teaching resources worldwide:

• FALCON (Fellowship in Anatomic deLineation and CONtouring): ESTRO’s delineation programme that can be used during teaching courses or remotely during online workshops. Nine FALCON online contouring workshops will be organised in 2018.

• DOVE (Dynamic Oncology Virtual ESTRO): e-library giving access to educational and scientific material such as articles, conference abstracts, webcasts, e-posters, slides, contouring cases, guidelines...Accessible from estro.org org homepage.

View the calendars of the 2018 live teaching courses and the FALCON online contouring workshops on www.estro.org/school

Abou

t



The European Association of Urology (EAU)

Founded in 1972, the European Association of Urology (EAU) represents the leading authority within Europe on urological practice, research and education. Over 15,000 medical professionals have joined its ranks and contribute to our mission: To raise the level of urological care throughout Europe and beyond. With the goal to create a dynamic network, the EAU supports medical professionals active in the field of urology through many of its scientific, professional, educational and awareness-building initiatives: • Career Development Whether you are a resident, a young urologist or an experienced specialist, the EAU

supports urologists throughout their career with programmes for continuing medical education and certification. We offer several educational programmes developed by the European School of Urology (ESU), scholarships and clinical visits. One of the most important tools to continue your professional development is UROsource, the EAU learning library for urologists. With over 50,000 items of scientific content it is the single largest knowledge base available today in the field of urology.

• Clinical Guidelines For any successful clinician, having the most up-to-date evidence-based

recommendations on hand is crucial for the successful treatment of your patients. The EAU Guidelines are unparalleled in that regard and used all across the world. They are comprehensively updated on an annual basis and freely accessible for all members.

• Political Activities Urologists are bound by national and, increasingly, international laws that govern

treatment options and patient care. The EAU brings together the voices of medical professionals, researchers, innovators and patients on a European platform to keep urological topics on the agendas of the authorities.

• Networking with Peers The EAU offers a wide range of events and courses to interact with the best specialists

in the field of urology. The Annual EAU Congress is the largest urology-related event in the world where you can network with like-minded professionals.

Abou

t


• Advancing Urological Science Our journal, European Urology, has been a prestigious urological forum for over 35

years, and is currently read by more than 20,000 urologists. It is one of the most widely-cited medical journals in the world and, with an impact factor of 14,976 leading in its field. Members have free access to full-text articles. The second official publication of the EAU is European Urology Focus (EU Focus),the new sister journal to European Urology. Each issue will include a series of invited, thematic reviews, together with original reports, correspondence and introductory editorials on a wide range of urological issues.

If you are interested in joining the largest international urological community in Europe, please visit www.uroweb.org/membership and find out what other benefits the EAU membership has to offer.

Abou

t



The European School of Urology (ESU)

The European School of Urology (ESU), on behalf of the EAU Education Office, responds to the education and training needs of urologists. Through various activities, the ESU stimulates, coordinates and organises all post-graduate teaching, education and hands-on training offered by the EAU.

With the ESU’s focus on knowledge-sharing and skills development, it provides support to doctors at any stage of their career in urology and to allied medical professionals. To enhance and facilitate the learning experience, the ESU employs both online technology and traditional teaching methods in its courses offered during the Annual EAU Congress and accredited meetings. This makes the ESU a front-line educational resource for professionals in urology. Over 16,000 medical professionals, world-wide, benefit from the ESU’s activities and projects, contributing to forward-looking solutions in medical education and professional growth.

The ESU’s success is anchored on the continued support of the ESU faculty, a community of 150 opinion leaders and experts in various urological specialties. They invest their time and expertise to all teaching activities on a voluntary basis, and we are grateful for their commitment to improve medical education and contribute to the progress of international urology.

To learn more about the European School of Urology, visit www.uroweb.org/education or contact the ESU at [email protected].

ESU BoardJoan Palou, Barcelona (ES) ChairmanJavier Angulo, Madrid (ES)Marko Babjuk, Prague (CZ)Thorsten Bach, Hamburg (DE)Marcus Drake, Bristol (GB)Evangelos Liatsikos, Patras (GR)Alex Mottrie, Aalst (BE) - Ex-OfficioJens Rassweiler, Heilbronn (DE) - Ex-OfficoOlivier Traxer, Paris (FR)Ben Van Cleynenbreugel, Leuven (BE)Henk Van Der Poel, Amsterdam (NL) - ConsultantJeroen Van Moorselaar, Amsterdam (NL)Hein Van Poppel, Leuven (BE) - Ex-Officio

Abou

t


The EAU Section of Urological Imaging (ESUI)

The ESUI, a section of the European Association of Urology, aims to increase the knowledge and integrate the know-how on imaging techniques among urologists. With its emphasis on multidisciplinary strategies and goal to improve collaboration with related specialties and affiliates, including radiologists and nuclear medicine physicians, the ESUI offers various activities to its members and other urological professionals.

To complement the EAU’s scientific and educational initiatives, the ESUI organises courses and training during its meetings and participates in the EAU’s broader educational strategies. Over the years, the ESUI’s membership has steadily expanded and its long-term strategies include knowledge-sharing with organisations and specialists groups not only within the urological community but also with other medical disciplines.

ActivitiesThe ESUI organises meetings to present urological imaging at different podia in Europe on a regular basis. One of the main platforms is its annual meeting held in various European cities. These meetings address controversial issues in urology, particularly new developments and challenges in urological imaging, its role in optimal diagnostic and treatment modalities, and the exchange of know-how among the international experts.

Further on, the ESUI is organising and endorsing clinical trials that evaluate urological imaging in clinical settings. They also organise surveys that address current issues and controversies on a European level. Finally the ESUI is also active in the EAU guidelines process by providing expertise in urological imaging.

ESUI Board ESUI Chairman Prof. Georg Salomon, Hamburg (DE)ESUI Board Dr. Hashim Uddin Ahmed, London (GB)ESUI Board Dr. Brendan Carey, Leeds (GB)ESUI Board Dr. Massimo Mischi, Eindhoven (NL)ESUI Board Prof. Dr. Manuel Ritter, Mannheim (DE)ESUI Board Dr. Vincenzo Scattoni, Milan (IT)ESUI Board Prof. Arnauld Villers, Lille (FR)Ex YAU Officio Dr. Jurgen Futterer, Nijmegen (NL)


Cutting-edge Science at Europe’s largest Urology Congress

www.eau18.org

Register now for the early fee!

Deadline: 15 January 2018

33rd Annual EAU

Congress

Scientific Programme

Cutting-edge Science at Europe’s largest Urology Congress

www.eau18.org

Register now for the early fee!

Deadline: 15 January 2018

33rd Annual EAU

Congress


Thur

sday

, 16

Nove

mbe

r

Scientific Programme - Thursday, 16 November

6th Meeting of the EAU Section on Urological Imaging (ESUI)

Time: 08.30 - 18.30Location: Room H1

08.30 - 08.35 Welcome by the ESUI G. Salomon, Hamburg (DE)

08.35 - 10.00 Improving effectiveness in diagnosis of prostate cancer - Part 1 Moderators: J. Futterer, Nijmegen (NL) T. Loch, Flensburg (DE) A. Villers, Lille (FR)

08.35 - 08.50 What needs to be included in cost-effectiveness calculations in prostate cancer diagnosis?

M. De Rooij, Nijmegen (NL)08.45 - 08.50 Discussion

08.50 - 09.15 Point and counterpoint in prostate cancer diagnosis 2.0: MRI before primary biopsy: Let’s break the bank with the costs?

08.50 - 09.00 Yes, this will break the bank N. Mottet, Saint-Étienne (FR)09.00 - 09.10 No, this is cost-effective H. Ahmed, London (GB)09.10 - 09.15 Discussion

09.15 - 09.30 What is more effective to select patients for prostate biopsy: Imaging vs. biomarkers

S. Nordström, Stockholm (SE)09.25 - 09.30 Discussion

09.30 - 09.45 Quality issues of mp-MRI: The problem of re-do MRI and cost-effectiveness

J. Walz, Marseille (FR)09.40 - 09.45 Discussion

09.45 - 10.00 What is an acceptable false negative rate in the detection of prostate cancer?

M. Roobol, Rotterdam (NL)09.55 - 10.00 Discussion

Thur

sday

, 16

Nove

mbe

r



10.00 - 10.30 Coffee break & poster viewing

10.30 - 12.00 Increasing the performance in the treatment of renal cell cancer Moderators: M. Ritter, Mannheim (DE) S. Siracusano, Trieste (IT) J. Walz, Marseille (FR)

10.30 - 10.45 3D-modeling of vascular anatomy for partial nephrectomy V. Ficarra, Udine (IT)10.40 - 10.45 Discussion

10.45 - 11.00 Active surveillance in renal cell cancer: When to switch to active treatment?

A. Volpe, Novara (IT)10.55 - 11.00 Discussion

11.00 - 11.15 Assessment of response to targeted therapy in metastatic RCC by texture analysis

N. Wagener, Mannheim (DE)11.10 - 11.15 Discussion

11.15 - 11.30 Expect the best, prepare for the worst: Prediction of adherent perirenal fat

V. Ficarra, Udine (IT)11.25 - 11.30 Discussion

11.30 - 11.45 Are we at the same level? Long term outcome of focal therapy of small renal masses vs. partial nephrectomy

S. Joniau, Leuven (BE)11.40 - 11.45 Discussion

11.45 - 12.00 Summary and questions

12.00 - 13.00 Industry lunch symposium, see pages 57 to 61 for more information


Thur

sday

, 16

Nove

mbe

r


13.00 - 14.10 Molecular imaging in Urology: Joint sessions of ESUI and EANM Moderators: S. Fanti, Bologna (IT) V. Scattoni, Milan (IT)

13.00 - 13.15 Cost-effectiveness and improvement of cancer control with PET/CT: Are we doing really better?

S. Fanti, Bologna (IT)13.10 - 13.15 Discussion

13.15 - 13.30 Welcome back: Fluciclovine-PET in the management of prostate cancer

T. Bach-Gansmo, Oslo (NO)13.25 - 13.30 Discussion

13.30 - 13.45 PSMA and the androgen receptor: A way to improve treatment monitoring of metastatic prostate cancer?

R. Schiavina, Bologna (IT)13.40 - 13.45 Discussion

13.45 - 14.00 New PET-tracers for renal cell cancer R. Delgado-Bolton, Logroño (ES)13.55 - 14.00 Discussion

14.00 - 14.10 Questions and Answers 14.10 - 14.55 Poster session and best abstract award Moderators: M. Mischi, Eindhoven (NL) G. Salomon, Hamburg (DE)

E01: Feasibility Study for avoiding or postponing biopsy using improved imaging: Negative predictive value of micro-ultrasound for subjects with low PSAD

A. Astobieta, Bilbao (ES) Discussion

E02: Diagnostic accuracy of MRI-Transrectal Ultrasound Fusion prostate Biopsy in men with previous prostate biopsies: Preliminary results of the FUPROS16 project

D. Lopez-Ruiz, Cordoba (ES) Discussion

Thur

sday

, 16

Nove

mbe

r



E06: Ultrasonographic study in patients affected by Peyronie’s disease with absence of palpable plaques or deformity of the penis

L. Dell’Atti, Ferrara (IT)

Discussion

E04: MR spectroscopy provides distinction between malignant clear cell renal cancers and indolent subtypes

S. Del Vecchio, Woolloongabba (AU)

Discussion

E05: 11C-choline PET-guided salvage intensity modulated radiotherapy with simultaneous integrated boost for isolated pelvic and para-aortic prostate cancer nodal recurrences: Minimal adverse effects

K. Jethwa, Rochester (US)

Discussion E03: Ga-68 PSMA PETCT response to androgen deprivation

therapy in patients with prostate cancer V. Murthy, Mumbai (IN)

Discussion

14.46 - 14.55 Award best abstract G. Salomon, Hamburg (DE)

14.55 - 15.20 Coffee break & poster viewing

15.20 - 16.30 Improved management for urothelial cancer Moderators: M. Kriegmair, Mannheim (DE) S. Siracusano, Trieste (IT)

15.20 - 15.35 Standard work-up for micro-hematuria: What do the EAU guidelines tell?

M. Babjuk, Prague (CZ)15.30 - 15.35 Discussion


Thur

sday

, 16

Nove

mbe

r


15.35 - 15.50 MRI in local staging of bladder cancer C. Roy, Strasbourg (FR)15.45 - 15.50 Discussion

15.50 - 16.05 Multiparametric cystoscopy M. Kriegmair, Mannheim (DE)16.00 - 16.05 Discussion

16.05 - 16.20 Immunotherapy: Imaging assessment of treatment response N. Mehra, Nijmegen (NL)16.15 - 16.20 Discussion

16.20 - 18.15 Improving effectiveness in diagnosis of prostate cancer - Part 2 Moderators: A. Villers, Lille (FR) H. Wijkstra, Amsterdam (NL)

16.20 - 16.50 Point and counterpoint in prostate cancer diagnosis: How to manage PI-RADS 3 lesions

16.20 - 16.30 Can enhanced TRUS solve the problem? G. Salomon, Hamburg (DE)16.30 - 16.40 Can predictive tools and biomarkers solve the problem? B. Hadaschik, Essen (DE) 16.40 - 16.50 Discussion

16.50 - 17.05 Up-date from the ESUR/ESUI MRI certification initiative J. Walz, Marseille (FR)17.00 - 17.05 Discussion

17.05 - 17.20 Transrectal or transperineal approach for fusion biopsy? C. Kastner, Cambridge (GB)17.15 - 17.20 Discussion

17.20 - 17.35 High resolution ultrasound and fusion biopsy L. Budäus, Hamburg (DE)17.30 - 17.35 Discussion

17.35 - 18.15 How to increase the performance of your prostate cancer diagnostic team

17.35 - 17.45 The radiologist’s point of view O. Rouviere, Lyon (FR)

Thur

sday

, 16

Nove

mbe

r



17.45 - 17.55 The urologist’s point of view C. Moore, London (GB)

17.55 - 18.05 The pathologist’s point of view R. Montironi, Ancona (IT)

18.05 - 18.15 Discussion

18.15 - 18.20 Summary and end of programme G. Salomon, Hamburg (DE)


Thur

sday

, 16

Nove

mbe

r


ESU Course: Interactive discussion on clinical scenarios in the management of localized, advanced and metastatic kidney cancer Time: 09.00 - 12.30 hrs.Location: Room H2Chair: Alessandro Volpe, Novara (IT)Faculty: Axel Bex, Amsterdam (NL) Markus Kuczyk, Hannover (DE)

Aims and objectivesA constant and rapid evolution of treatment strategies for localized and advanced renal tumors has occurred in the last 15 years. The increasing knowledge of histology and biological behavior of small renal masses, the development and progressive adoption of minimally invasive surgical techniques and alternative treatment options for low-risk renal tumors, the continuous discovery and implementation of active targeted drugs and novel immunotherapy regimens for treatment of metastatic disease make clinical management of renal tumors increasingly interesting and challenging.

This ESU course has the objective to give the participants recommendations on the diagnosis and multidisciplinary clinical management of localized and advanced renal tumors based on the presentation of clinical cases. An interactive discussion between faculty and attendees on clinical cases and controversial topics will be favoured.

09.00 - 09.05 European School of Urology: A unique possibility for urological education

Alessandro Volpe, Novara (IT)

09.05 - 09.55 Small renal masses Imaging of small renal masses Role of percutaneous renal tumor biopsy, ablative techniques, active

surveillance Partial nephrectomy: Impact on oncological outcomes, renal function,

overall survival Surveillance strategies after surgical treatment

Thur

sday

, 16

Nove

mbe

r



09.55 - 10.40 Renal tumors with high surgical complexity Risk-benefit trade-off of partial vs. radical nephrectomy Utility of nephrometry classifications Determimants of postoperative renal function after partial nephrectomy:

warm ischemia time, preserved volume of healthy renal parenchyma, baseline renal function

Techniques of partial nephrectomy and management of complications

10.40 - 11.10 Coffee break

11.10 - 12.30 Advanced and metastatic renal tumors Systemic targeted therapy and immunotherapy for advanced RCC Current role of cytoreductive nephrectomy and metastasectomy Role of adjuvant therapy after surgery for high-risk disease Clinical application and utility of genomic characterization in advanced

RCC

12.30 Close


Thur

sday

, 16

Nove

mbe

r


ESU Course on “Bladder cancer: A practical approach” Time: 13.00 - 16.00 hrs.Location: Room H2Faculty: Joan Palou, Barcelona (ES) Joaquim Bellmunt, Boston (US) Fred Witjes, Nijmegen (NL)

Aims and Objectives The multidisciplinary approach to bladder cancer is one of the most important factors for the improvement of the daily care of the patients. It is not always straightforward to deal with diagnostic and therapeutic issues in bladder cancer. There are several papers showing that specialists are not commonly following the guidelines. What´s wrong? Why?The aim of the this course is to talk to experts and interact with the audience presenting clinical cases to evaluate and challenge from basic concepts and established treatments, to new possibilities that are not always standardized and/or adopted by the EAU guidelines. To review and update the diagnosis and management of bladder cancerTo evaluate different treatment options in bladder cancerTo challenge the daily practice

13.00 - 13.05 European School of Urology: A unique possibility for urological education

Joan Palou, Barcelona (ES)

13.05 - 13.20 What do we need to know and what do we need to improve in the EAU Guidelines

13.20 - 14.40 Clinical cases in NMIBC

14.40 - 15.00 Coffee break

15.00 - 16.00 Clinical cases in MIBC

16.00 Close

Thur

sday

, 16

Nove

mbe

r



EMUC Symposium on Genitourinary Pathology and Molecular Diagnostics (ESUP)

Emerging Biomarkers in Genitourinary Tumors

Time: 14.30 - 17.30 hrs.Location: Room A

14.30 - 14.40 Welcome and introduction Chairs: Urologist - Alberto Briganti, Milan (IT) Pathologist - Rodolfo Montironi, Ancona (IT) Pathologist - Antonio Lopez-Beltran, Lisbon (PT) Urologist - Hein Van Poppel, Leuven (BE)

14.40 - 14.50 Biomarker, molecular and technological advances in genitourinary pathology

Pathologist - Rodolfo Montironi, Ancona (IT) Urologist - Hein Van Poppel, Leuven (BE)

14.50 - 15.20 Urologic pathology: From pure morphology to predictive medicine Urological researcher - Kerstin Junker, Homburg (DE)

15.20 - 15.50 Circulating tumor cells and biomarkers in genitourinary tumors Urological researcher - Yves Allory, Paris (FR)

15.50 - 16.20 Urinary biomarkers for prostate cancer Pathologist - Michelangelo Fiorentino, Bologna (IT)

16.20 - 16.50 MiRNA in genitourinary tumors Pathologist - Antonio Lopez-Beltran, Lisbon (PT)

16.50 - 17.20 PDL1 testing and immunotherapy for genitourinary organs Pathologist - Georges Netto, Alabama (US)

17.20 - 17.30 Take home message: Emerging biomarkers in genitourinary tumors

Pathologist - Antonio Lopez-Beltran, Lisbon (PT) Urologist - Alberto Briganti, Milan (IT)

17.30 Close

Frid

ay,

17 N

ovem

ber


Scientific Programme - Friday, 17 November

9th European Multidisciplinary Meeting on Urological Cancers (EMUC17)

Multidisciplinary strategies in urogenital cancers Time: 08.15 - 18.15 hrs.Location: Auditorium

08.15 - 08.20 Welcome and Introduction Medical oncologist Thomas Powles, London (GB) - ESMO Radiation oncologist Peter Hoskin, Northwood (GB) - ESTRO Urologist Hein van Poppel, Leuven (BE) - EAU

08.20 - 10.05 Detection and treatment of clinically significant prostate cancer Chairs: Radiologist - Raymond Oyen, Leuven (BE) Radiation oncologist - Thomas Wiegel, Ulm (DE) Urologist - Francesco Montorsi, Milan (IT)

08.20 - 09.00 MRI before biopsy for all men? YES Urologist - Hashim Ahmed, London (GB) Radiologist - Harriet Thoeny, Berne (CH) vs NO Radiologist - Olivier Rouvière, Lyon (FR) Urologist - Jochen Walz, Marseille (FR)

Last judgement: Urologist - Nicolas Mottet, Saint-Étienne (FR)

09.00 - 09.15 Index lesion in prostate cancer: Myth or reality? Pathologist - Mark Rubin, New York (US)

09.15 - 09.20 Questions and answers

09.20 - 09.50 Will level 1 evidence influence our practice in focal therapy? YES Urologist - Mark Emberton, London (GB) vs NO Radiation oncologist - Alberto Bossi, Villejuif (FR) Last judgement: Urologist - Arnauld Villers, Lille (FR)


Frid

ay,

17 N

ovem

ber



10.05 - 10.50 The optimal primary treatment of prostate cancer: A focus on the ProtecT study

Chairs: Radiologist - Raymond Oyen, Leuven (BE) Radiation oncologist - Thomas Wiegel, Ulm (DE) Urologist - Francesco Montorsi, Milan (IT)

10.05 - 10.15 ProtecT: What have we learnt? Radiation oncologist - Malcolm Mason, Cardiff (GB)

10.15 - 10.25 Would modern staging change the results? Urologist - Silvan Boxler, Berne (CH)

10.25 - 10.35 The statistician point of view Biostatistician - Mahesh Parmar, London (GB)


10.50 - 11.20 Coffee break and poster viewing

11.20 - 12.35 Immunotherapy in urological cancers Chairs: Urologist - Alexander Govorov, Moscow (RU) Pathologist - Rodolfo Montironi, Ancona (IT)

11.20 - 11.35 Biological basics of immune therapy Medical oncologist - TBC

11.35 - 11.50 Prostate cancer Medical oncologist - Silke Gillessen, St. Gallen (CH)

11.50 - 12.05 Bladder cancer Medical oncologist - Andrea Necchi, Milan (IT)

12.05 - 12.20 Kidney cancer Medical oncologist - Thomas Powles, London (GB)


Frid

ay,

17 N

ovem

ber



12.35 - 12.45 Summary of EAU Prostate Cancer Centre Consensus Meeting (EPCCCM)

Urologist - Manfred Wirth, Dresden (DE)

12.45 - 14.00 Lunch break and poster viewing

13.00 - 14.00 Industry session, see pages 57 to 61 for more information

14.00 - 15.15 Educational session on testis cancer Chairs: Clinical oncologist - Jan Oldenburg, Oslo (NO) Radiation oncologist - Peter Hoskin, Northwood (GB) Urologist - Fred Witjes, Nijmegen (NL) Pathologist - Michelangelo Fiorentino, Bologna (IT)

14.00 - 14.15 Management of stage 1 Urologist - Peter Albers, Düsseldorf (DE)

14.15 - 14.30 Management of metastatic disease Medical oncologist - Karim Fizazi, Villejuif (FR)

14.30 - 15.15 Case discussion “Stage I seminoma” Case presenter: Clinical oncologist - Jan Oldenburg, Oslo (NO) Urologist - Peter Albers, Düsseldorf (DE) Medonc view: Medical oncologist - Karim Fizazi, Villejuif (FR) Radonc view: Radiation oncologist - Gert De Meerleer, Leuven

(BE) Case discussion “Residual disease” Case presenter : Clinical oncologist - Jan Oldenburg, Oslo (NO) Case discussants: Urologist - Peter Albers, Düsseldorf (DE) Medical oncologist - Karim Fizazi, Villejuif (FR) Radiation oncologist - Gert De Meerleer, Leuven

(BE)

15.15 - 15-30 Best of journals session: Radiotherapy Chairs: Radiation oncologist - Bradley Pieters, Amsterdam (NL) Radiation oncologist - Ananya Choudhury, Manchester

(GB) 15.30 - 16.00 Coffee break and poster viewing

Frid

ay,

17 N

ovem

ber



16.00 - 17.45 Educational session on bladder cancer Chairs: Radiotherapist - Anne Kiltie, Oxford (GB) Urologist - George Thalmann, Berne (CH) Pathologist - Antonio Lopez-Beltran, Lisbon (PT) Medical oncologist - Maria De Santis, Coventry (GB)

16.00 - 16.20 Bladder preservation: How and for whom? Radiation oncologist - Nicholas James, Birmingham (GB)

16.20 - 16.35 Lymph node dissection: How high is enough? Urologist - Stephen Boorjian, Rochester (US)

16.35 - 16.50 Molecular sub-types and implications for prognosis and therapy Pathologist - Antonio Lopez-Beltran, Lisbon (PT)

16.50 - 17.45 Case discussion Case presenter: Urologist - George Thalmann, Berne (CH) Case discussants: Radiation oncologist - Nicholas James,

Birmingham (GB) Urologist - Stephen Boorjian, Rochester (US) Medical oncologist - Maria De Santis, Coventry (GB)

17.45 - 18.45 Industry sessions, see pages 57 to 61 for more information

Satu

rday

, 18

Nove

mbe

r


Scientific Programme - Saturday, 18 November

FALCON contouring workshop

Time: 08.45 - 10.15 hrs.Location: Room E123Tutor: Ines Nobre Góis, Coimbra (PT)Chair: Maarten Hulshof, Amsterdam (NL)Panelists: Anne Kiltie, Oxford (GB) Bradley Pieters, Amsterdam (NL)

FALCON (Fellowship in Anatomic delineation and CONtouring) is the multifunctional ESTRO platform for contouring and delineation. Attending a FALCON workshop offers the opportunity for individual professionals• to validate their contouring practice during live workshops by comparing them with those

from experts and other participants• to learn the indications proposed by the experts that coordinate the workshops• to discuss with other participants, experts and panelists• to communicate and use the delineation guidelines in order to further integrate

themselves into daily practice

Target audience:The delineation workshops are aimed at junior clinical or radiation oncologists wanting to improve their contouring skills or more senior specialists wanting to refresh and validate their knowledge and skills in this field.

Structure of the workshops:• Explanation of the contouring software• Presentation of the clinical case• 1st round of contouring (20 minutes)• Presentation of the delineation guidelines• 1st round of contouring (15 minutes)• Discussion between experts and participants

Satu

rday

, 18

Nove

mbe

r



Uropathology training workshop

Joint histological evaluation of prostate specimens by the uropathologist and the clinician: We can do it better with Epstein

Time: 17.45 - 18.45 hrs.Location: Room E123

The one-hour workshop will be presented by Prof. Jonathan Epstein from Baltimore (US). Joining Prof. Epstein as chairs are Prof. Antonio Lopez-Beltran (PT) and Prof. Rodolfo Montironi (IT).The joint histological evaluation of specimens by the clinician and uropathologist can produce much more clinical and prognostic information than that contained in the final histopathology report. Both the clinician and uropathologist can benefit from such an approach. The former will more clearly understand and explain the preoperative features of the cancer, the intraoperative findings, and postoperative follow-up of the patient. The experience acquired would help improve him/her diagnostic and prognostication capabilities and surgical skill. The uropathologist will learn the great clinical significance of his/her daily routine. The course will be based on the projection and discussion of virtual slides and will focus on Epstein criteria for active surveillance and prostate cancer grading.

Satu

rday

, 18

Nove

mbe

r





08.15 - 08.30 Announcement 3 best unmoderated posters Chairs: Clinical oncologist - Jan Oldenburg, Oslo (NO) Urologist - Michiel Sedelaar, Nijmegen (NL)

08.30 - 10.15 Oligometastatic kidney cancer Chairs: Radiation oncologist - Vincent Khoo, London (GB) Urologist - Hein Van Poppel, Leuven (BE) Medical oncologist - Thomas Powles, London (GB) Pathologist - Ferran Algaba, Barcelona (ES) 08.30 - 08.45 The optimal timing of cytoreductive nephrectomy Urologist - Axel Bex, Amsterdam (NL)

08.45 - 09.00 Expanding knowledge of adjuvant therapy Urologist - Umberto Capitanio, Milan (IT)

09.00 - 09.15 Potential biomarkers for decision making Urological researcher - Kerstin Junker, Homburg (DE)

09.15 - 09.25 Can local ablation delay the use of systemic therapy for oligometastasis - Radiation therapy

Radiation oncologist - Piet Ost, Ghent (BE)

09.25 - 10.15 Case discussion Case presenter: Urologist - Umberto Capitanio, Milan (IT) Case discussants: Urologist - Axel Bex, Amsterdam (NL) Urological researcher - Kerstin Junker,

Homburg (DE) Radiation oncologist - Piet Ost, Ghent (BE)

10.15 - 10.45 Coffee break and poster viewing

Satu

rday

, 18

Nove

mbe

r



10.45 - 11.25 Oral presentations of the 6 best abstracts Chairs: Medical oncologist - Susanne Osanto, Leiden (NL) Urologist - Hein Van Poppel, Leuven (BE) Radiation therapist - Barbara Jereczek-Fossa, Milan (IT)

11.25 - 11.45 Highlights of Advanced Prostate Cancer Consensus Conference (APCCC2017)

Medical oncologist - Silke Gillessen, St. Gallen (CH)

11.45 - 12.15 Is there a shift for selection criteria and definition of reclassification for prostate cancer on active surveillance?

Introduction: Pathologist - Rodolfo Montironi, Ancona (IT) Speaker: Pathologist - Jonathan I. Epstein, Baltimore (US)

12.15 - 12.45 Stand-alone session on recent updates/novelties

12.45 - 14.00 Lunch break and poster viewing

13.00 - 14.00 Industry sessions, see pages 57 to 61 for more information

14.00 - 16.05 Management of loco/regional recurrences (prostate/penile cancer) Chairs: Medical oncologist - Silke Gillessen, St. Gallen (CH) Urologist - Georg Salomon, Hamburg (DE) Radiation therapist - Cesare Cozzarini, Milan (IT)

14.00 - 14.15 MRI/whole body MRI Radiologist - Frédéric Lecouvet, Brussels (BE)

14.15 - 14.35 Use of PET/CT Nuclear medicine - Stefano Fanti, Bologna (IT)

14.35 - 14.45 Salvage surgery after radiotherapy Urologist - Steven Joniau, Leuven (BE)

14.45 - 15.00 Salvage treatment after radical prostatectomy Radiation oncologist - Alberto Bossi, Villejuif (FR)

15.00 - 15.15 Management of local recurrences in penile cancer Urologist - Chris Protzel, Rostock (DE)

Satu

rday

, 18

Nove

mbe

r



15.15 - 16.05 Case discussion Case presenter: Urologist - Gianluca Giannarini, Udine (IT) Case discussants: Radiologist - Frédéric Lecouvet, Brussels (BE) Nuclear medicine - Stefano Fanti, Bologna (IT) Urologist - Steven Joniau, Leuven (BE) Radiation oncologist - Alberto Bossi, Villejuif (FR) Urologist - Chris Protzel, Rostock (DE) 16.05 - 16.35 Coffee break and poster viewing

16.35 - 16.50 Best of journals: Surgery Chairs: Urologist - Maurizio Brausi, Modena (IT) Urologist - Jochen Walz, Marseille (FR)

16.50 - 17.45 Educational session: Challenging cases in the management of upper urinary tract TCC

Chairs: Urologist - Evanguelos Xylinas, Paris (FR) Urologist - Joan Palou, Barcelona (ES)

Clinical case discussion (including peri-operative chemo, imaging, pathologist, biopsy)

Case presenter: Urologist - Evanguelos Xylinas, Paris (FR) Case discussants: Clinical Oncologist - Ananya Choudhury,

Manchester (GB) Urologist - Morgan Roupret, Paris (FR) Radiologist - Raymond Oyen, Leuven (BE) Pathologist - Sara Falzarano, Cleveland (US)

Sund

ay, 1

9 No

vem

ber


Scientific programme - Sunday, 19 November



08.30 - 08.45 Announcement 3 best unmoderated posters Chairs: Clinical oncologist - Jan Oldenburg, Oslo (NO) Urologist - Igle-Jan de Jong, Groningen (NL)

08.45 - 09.00 Best of journals: Medical oncology Chairs: Medical oncologist - Cora Sternberg, Rome (IT) Medical oncologist - Andrea Necchi, Milan (IT)

09.00 - 09.15 Drug repurposing opportunities in uro-oncology Chairs: Medical oncologist - Cora Sternberg, Rome (IT) Urologist - Hein van Poppel, Leuven (BE) Speaker: Dr. Director Anticancer fund - Gauthier Bouche,

Strombeek-Bever (BE)

09.15 - 11.00 Evolving concepts in metastatic prostate cancer Chairs: Medical oncologist - Cora Sternberg, Rome (IT) Urologist - Jeffrey Karnes, New York (US) Radiation therapist - David Dearnaley, Sutton (GB)

09.15 - 09.30 How should we treat our metastatic castrate sensitive patients? Radiation oncologist - Nicholas James, Birmingham (GB)

09.30 - 09.45 Monitoring patients with metastatic disease Radiologist - Anwar Padhani, Northwood (GB)

09.45 - 10.00 Treatment of the primary in metastatic patients Urologist - Markus Graefen, Hamburg (DE)

10.00 - 10.15 Molecular radiotherapy Radiologist - Uwe Haberkorn, Heidelberg (DE)

Sund

ay, 1

9 No

vem

ber


Scientific programme - Sunday, 19 November

10.15 - 11.00 Case discussion Urologist - Simon Brewster, Oxford (GB)

11.00 - 11.30 European Commission lecture Director General for Health and Food Safety - Xavier Prats Monné,

Barcelona (ES) 11.30 - 12.20 Take home messages 11.30 - 11.40 Radiologist - Raymond Oyen, Leuven (BE)11.40 - 11.50 Urologist - Igle-Jan De Jong, Groningen (NL) 11.50 - 12.00 Clinical oncologist - Jan Oldenburg, Oslo (NO)12.00 - 12.10 Radiation oncologist - Bradley Pieters, Amsterdam (NL)12.10 - 12.20 Pathologist - Rodolfo Montironi, Ancona (IT) 12.20 - 12.30 Closing remarks Clinical oncologist - Jan Oldenburg, Oslo (NO), ESMO Radiation oncologist - Peter Hoskin, Northwood (GB), ESTRO Urologist - Hein Van Poppel, Leuven (BE), EAU

ESU

HOT


Hands-on Training Courses (HOT)

ESU/ESUT/ESUI Hands-on Training in MRI Fusion biopsy

Time: Friday, 17 November 11.00 - 13.00 hrs. Friday, 17 November 14.00 - 16.00 hrs.Location: Room B123Course coordinator: L. Budäus, Hamburg (DE)Tutors: T. Loch, Flensburg (DE) S. Kruck, Tubingen (DE) L. Budäus, Hamburg (DE)

Aims and Objectives MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow. The course will provide an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. During the second half of the course, the participants are able to try out 5 different Fusion biopsy machines in small groups, changing every 10 min.

ESU

HOT



ESU/ERUS Hands-on Training courses in Robotic surgery

Time: Friday, 17 November 09.15 - 10.45 hrs. Friday, 17 November 11.30 - 13.00 hrs. Friday, 17 November 13.30 - 15.00 hrs. Friday, 17 November 15.30 - 17.00 hrs. Saturday, 18 November 09.15 - 11.00 hrs. Saturday, 18 November 11.45 - 13.15 hrs. Saturday, 18 November 13.45 - 15.15 hrs. Saturday, 18 November 15.45 - 17.15 hrs.Location: Room B123Tutors: A. Ploumidis, Athens (GR) TBC

Aims and objectivesDuring the advanced course the trainee can practice partial and entire robotic procedures using the novel simulator software on the Robotix mentor. There will be two advanced virtual robotic procedural training courses.

The main aims of this 90 minutes course are: improving the participants’ control-skills and hand-eye-coordination, as well as an objective benchmarking of console performance and an introduction into standardized surgical steps in robot-assisted procedures. The training is adjustable to your level of experience and covers from basic to advanced exercises.

Improve your robotic surgery skills in the following areas:• Endowrist manipulation• Camera Control• 3rd Arm Control• Needle Placement and Driving• Suturing and Knot Tying• Partial or full procedural surgery

ESU

HOT



ESU/ESUT/ESUI Hands-on Training for urologists in the diagnosis and management of prostate cancer

Time: Friday, 17 November 09.30 - 12.30 hrs. Friday, 17 November 13.30 - 16.30 hrs.Location: Room ATutors: C. Moore, London (GB) J. Futterer, Nijmegen (NL) O. Rouviere, Lyon (FR)

Aims and objectivesTo understand how to use OSIRIX image viewer or a PACS readerHow to display a patient’s scansHow to split windows and pull up 4 images at onceHow to measure distancesTo understand the basic concepts/principles behind different MRI sequencesT2-weighted imagingDWI-imagingDCE-imagingTo understand how to use the Likert scoring system to score MRIsTo understand briefly what features would lead to different Likert scores To understand how to use the PIRADSv2 scoring system to score MRIsTo understand the difference between Likert and PIRADs scoringTo understand briefly what features would lead to different PIRADsv2 scoresTo understand which order to view the different sequences in when interpreting prostate MRITo understand how to use the scoring proforma to score a prostate MRITo understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled.

Assessment: Hand-on baseline assessment of MRI interpretation Part 1 using OSIRIX software on Macs or PACS reader:To be able to use Macs and OSIRIX software or a PACS reader to look through prostate MRITo be able to identify the different sequences on prostate MRITo practice scoring prostate MRITo understand the important reporting features of prostate MRI

Lecture: Tips and Tricks for difficult areas in prostate MRI and limitations of prostate MRI To understand areas of difficulty in the prostate when assessing prostate MRITo be able to differentiate between normal and abnormal tissue in these difficult areas

ESU

HOT



To understand the limitations of prostate MRI

To understand how MRI can be used to influence external beam radiotherapy in men with prostate cancerTo understand how MRI can be used to influence focal therapy in men with prostate cancer/ metastatic disease


Faculty List

EMUC Faculty H. Ahmed, London (GB) P. Albers, Düsseldorf (DE) F. Algaba, Barcelona (ES) Y. Allory, Creteil (FR) J. Bellmunt, Boston (US) C. Bensalah, Rennes (FR) A. Bex, Amsterdam (NL) S. Boorjian, Rochester (US) J. Bosschieter, Amsterdam (NL) A. Bossi, Villejuif (FR) G. Bouche, Strombeek-Bever (BE) S. Boxler, Berne (CH) M. Brausi, Modena (IT) S. Brewster, Oxford (GB) A. Briganti, Milan (IT) L. Budäus, Hamburg (DE) U. Capitanio, Milan (IT) A. Choudhury, Manchester (GB) C. Cozzarini, Milan (IT) I-J. De Jong, Groningen (NL) G. De Meerleer, Ghent (BE) M. De Santis, Coventry (GB) D. Dearnaley, Sutton (GB) M. Emberton, London (GB) J. Epstein, Baltimore (US) S. Falzarano, Cleveland (US) S. Fanti, Bologna (IT) M. Fiorentino, Bologna (IT) K. Fizazi, Villejuif (FR) G. Giannarini, Udine (IT) S. Gillessen, St. Gallen (CH) A. Govorov, Moscow (RU) M. Graefen, Hamburg (DE) U. Haberkorn, Heidelberg (DE) N. Hayakawa, Tokyo (JP) P. Hoskin, Northwood (GB) M. Hulshof, Amsterdam (NL) N. James, Birmingham (GB) B. Jereczek-Fossa, Milan (IT)

S. Joniau, Leuven (BE) K. Junker, Homburg (DE) R. Karnes, Rochester (US) A. Kiltie, Oxford (GB) V. Khoo, London (GB) S. Kruck, Tübingen (DE) M. Kuczyk, Hanover (DE) F. Lecouvet, Brussels (BE) T. Loch, Flensburg (DE) A. Lopez-Beltran, Lisbon (PT) M. Mason, Cardiff (GB) R. Montironi, Ancona (IT) F. Montorsi, Milan (IT) N. Mottet, Saint-Étienne (FR) A. Necchi, Milan (IT) G. Netto, Birmingham (US) T. Nordström, Stockholm (SE) A. Ochoa Sanchez, Mexico City (MX) J. Oldenburg, Lørenskog (NO) S. Osanto, Leiden (NL) P. Ost, Ghent (BE) R. Oyen, Leuven (BE) A. Padhani, Northwood (GB) J. Palou, Barcelona (ES) M. Parmar, London (GB) B. Pieters, Amsterdam (NL) T. Powles, London (GB) X. Prats Monné, Brussel (BE) C. Protzel, Rostock (DE) M. Roobol, Rotterdam (NL) M. Rouprêt, Paris (FR) O. Rouviere, Lyon (FR) M. Rubin, Berne (CH) G. Salomon, Hamburg (DE) M. Sedelaar, Nijmegen (NL) C.N. Sternberg, Rome (IT) N. Thalmann, Berne (CH) H. Thoeny, Berne (CH) H. Van Poppel, Leuven (BE) A. Verbiest, Leuven (BE)


A. Villers, Lille (FR) A. Volpe, Novara (IT) J. Walz, Marseille (FR) T. Wiegel, Ulm (DE) M. Wirth, Dresden (DE) J. Witjes, Nijmegen (NL) E. Xylinas, Paris (FR)

ESUI FacultyH. Ahmed, London (GB)M. Babjuk, Prague (CZ)T. Bach-Gansmo, Oslo (NO)L. Budäus, Hamburg (DE)M. De Rooij, Nijmegen (NL)R. Delgado-Bolton, Logroño (ES)S. Fanti, Bologna (IT)V. Ficarra, Udine (IT)J. Futterer, Nijmegen (NL)B. Hadaschik, Essen (DE)C. Kastner, Cambridge (GB)S. Joniau, Leuven (BE) M. Kriegmair, Mannheim (DE)T. Loch, Flensburg (DE)N. Mehra, Nijmegen (NL)M. Mischi, Eindhoven (NL)R. Montironi, Ancona (IT)C. Moore, London (GB)N. Mottet, Saint-Étienne (FR)T. Nordström, Stockholm (SE) M. Ritter, Mannheim (DE)M. Roobol, Rotterdam (NL)O. Rouviere, Lyon (FR)C. Roy, Strasbourg (FR)G. Salomon, Hamburg (DE)V. Scattoni, Milano (IT)R. Schiavina, Bologna (IT)S. Siracusano, Trieste (IT)A. Villers, Lille (FR)A. Volpe, Novara (IT)N. Wagener, Mannheim (DE)J. Walz, Marseille (FR)

H. Wijkstra, Amsterdam (NL)ESU FacultyJ. Bellmunt, Boston (US)A. Bex, Amsterdam (NL)J. Palou, Barcelona (ES)M. Kuczyk, Hanover (DE)A. Volpe, Novara (IT)F. Witjes, Nijmegen (NL)

Faculty List


Continuing Medical Education Accreditation EMUC17

The ‘9th European Multidisciplinary Meeting on Urological cancers (EMUC)’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The ‘9th European Multidisciplinary Meeting on Urological cancers (EMUC)’ is designated for a maximum of (or ‘for up to’) 18 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME creditsEach medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

The event has also been accredited with 18 ESMO-MORA category 1 credits.


Continuing Medical Education Accreditation ESUI17

The `6th Meeting of the EAU Section of Urological Imaging (ESUI)’ (6 CME points) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The meeting is designated for a maximum of 6 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME creditsEach medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

Industry

Indu

stry


Industry Sessions

Industry Session by BLUE EARTH DIAGNOSTICS

Axumin™ (Fluciclovine (18F)) – A Newly Approved Imaging Option for Recurrent Prostate Cancer – A Scientific Update

Date: Thursday, 16 NovemberLocation: Room H1

12.00 - 12.05 Welcome and Introduction Frode Willoch, Oslo (NO)

12.05 - 12.20 The FALCON Trial – A Phase 3 Study to assess the clinical utility of fluciclovine (18F) PET/CT imaging in patients with prostate cancer with biochemical recurrence

Fergus Gleeson, Oxford (GB)

12.20 - 12.35 Clinical Experience of fluciclovine (18F) PET/CT imaging in men with suspected recurrent prostate cancer and PSA values <1ng/mL

Frode Willoch, Oslo (NO)

12.35 - 12.50 Initial experience with using (18F) Fluciclovine in biochemically recurrent prostate cancer

Dirk Wyndaele, Eindhoven (NL)

12.50 - 13.00 Summary and closing remarks Frode Willoch, Oslo (NO)

Indu

stry


Industry Sessions

Industry Session by SANOFI GENZYME

New horizons in the management of advanced prostate cancer

Date: Friday, 17 NovemberLocation: Auditorium

13.00 - 13.05 Welcome and introduction Gero Kramer, Vienna (AT)

13.05 - 13.20 Individualizing treatment choices based on the biology of the disease

Yohann Loriot, Paris (FR)

13.20 - 13.35 Progresses and promises in the management of metastatic prostate cancer

Gero Kramer, Vienna (AT)

13.35 - 13.50 Translating the evidence into clinical practice Amit Bahl, Bristol (GB)

13.50 - 14.00 Discussion and closing remarks Chairman – faculty – audience

Indu

stry


Industry Sessions

Industry Session by MSD

Immunotherapy Advances in Urologic Oncology

Time: Friday, 17 NovemberLocation: Auditorium

17.45 - 17.50 Welcome and introductions Chair: Cora Sternberg, Rome (IT)

17.50 - 18.05 Understanding the Mechanism of I-O Agents in GU Cancers Thomas Powles, London (UK)

18.05 - 18.20 Latest Data Releases in I-O for mUC Maria De Santis, Coventry (UK)

18.20 - 18.30 mUC Patient Case Studies Jurgen Gschwend, Munich (DE)

18.30 - 18.40 Q & A session with panel All

18.40 - 18.45 Closing Remarks Cora Sternberg, Rome (IT)

Indu

stry


Industry Sessions

Industry Session by IPSEN

Optimising treatment decisions in urological oncology

Time: Saturday, 18 NovemberLocation: Auditorium

13.0 - 13.10 Welcome and introduction Enrique Gallardo, Barcelona (ES)

13.10 - 13.30 Advanced prostate cancer: Changing landscape for individualised treatment

Peter Hammerer, Braunschweig (DE)

13.30 - 13.50 Advanced RCC: 2nd line treatment options Cezary Szczylik, Warsaw (PL)

13.50 - 14.00 Summary & closing Enrique Gallardo, Barcelona (ES)


Exhibition: Company Profiles

Exhi

bitio

n

C4

B3

B4C1

C2A5

A6

B2 B1A9 A4 A3 A2 A1

C3B5

Exhibition Floor Plan


Exhi

bitio

n

Exhibitors BoothASTELLAS C4ASTRAZENECA B3BLUE EARTH DIAGNOSTICS A5COOK MEDICAL A8EAU A3ESMO A1ESTRO A2EUROPA UOMO A4EXACT IMAGING B1HITACHI B5IPSEN C1INVIVO B2MDX HEALTH A9MSD C3NUCLEIX A7SANDOZ INTERNATIONAL GMBH C2SANOFI B4SYNERGO BY MEDICAL ENTERPRISES A6

A7 A8


Indu

stry

What science can do

AstraZeneca AstraZeneca is investigating combinations of biologic and small molecule therapies for the treatment of cancer. These combinations target the tumour directly and some help boost the body’s own immune system to induce tumourcell death.


Indu

stry

What science can do


www.esui18.org

ESUI187th Meeting of the EAU Sectionof Urological Imaging

8 November 2018Amsterdam, The Netherlands

In conjunction with the 10th European Multidisciplinary congress on Urological Cancers

An application hasbeen made to theEACCME® for CMEaccreditation ofthis event



Exhi

bitio

n

ASTELLAS PHARMA EUROPE LTD2000 Hillswood Drive, Chertsey, Surrey KT16 0RS UKT: 0203 379 8700W: www.astellas.eu

Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients worldwide. We are committed to the fight against cancer and to making innovative treatments available, that can extend and improve the lives of those suffering from cancer. To do this we focus our efforts in areas where we can develop best-in-class medicines, advancing treatments where there are real needs for patients. This has resulted in a number of treatments for various cancers moving through clinical development, with many more in early stage research. At Astellas, we’re focused on making changing tomorrow a reality.

ASTRAZENECA SPAIN Calle de Serrano Galvache, 56, 28033 Madrid, España T: +34 913 01 91 00 W: www.astrazeneca.com

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, having a deep-rooted heritage in Oncology and offering a portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and

Antibody Drug Conjugates – and by the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

BLUE EARTH DIAGNOSTICSThe Oxford Science Park, Magdalen Centre, Robert Robinson Avenue, Oxford OX4 4GAT: +441865784186F: +441865784004E: [email protected]

Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The Company’s first approved and commercially available product is Axumin™ (fluciclovine F 18), a novel molecular imaging agent approved in the United States and the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. The Company is backed by Syncona Limited, an investment company listed on the London Stock Exchange (LON: SYNC). For more information, visit: www.blueearthdiagnostics.com.


Exhi

bitio

n


COOK MEDICAL O’Halloran Road, V94 N8X2, Limerick, IrelandT: +353 61 334 440F: +353 61 334 441W: www.cookmedical.euE: [email protected]

A patient-first philosophy and innovative spirit have helped Cook become a leader in urology. With a focus on stone management and urologic oncology, we pride ourselves on providing quality solutions without compromise. By uniting with healthcare professionals around the world, we’re committed to advancing treatment and making a difference, together.

EUROPA UOMO Lange Gasthuisstraat 35–37, 2000 Antwerpen, BelgiumT: +32 33 389 151F: +32 33 389 152W: www.europa-uomo.org E: [email protected] FB: www.facebook.com/EuropaUomo

Europa Uomo, the European Prostate Cancer Coalition chaired by Ken Mastris (UK), represents 24 European countries and supports patient groups with prostate diseases in general and cancer in particular. Our aims include increasing awareness of prostate diseases, the support of individualized treatment based on optimal medical treatment with personalized patient care and patients’ advocacy as a priority focused on quality of life based on solidarity and mutual respect. Our expansion is based

on collaboration with the professional organizations to provide information on evidence based treatment, to educate men on holistic patient care and on solidarity in advocacy with other patient support groups. Bullet points:- A future where no man suffers with or dies from prostate cancer- To work for all prostate cancer patients in Europe, under one umbrella, for better treatment, care and quality of life- To support national organisations to deliver services effectively, efficiently and in line with national priorities

EUROPEAN ASSOCIATION OF UROLOGY (EAU)Mr. E.N. van Kleffensstraat 5, 6842 CV Arnhem, The NetherlandsT: +31 263 89 06 80F: +31 263 89 06 74W: www.uroweb.org E: [email protected]

The European Association of Urology is a non-profit organisation which supports medical professionals working in the field of urology through many of its scientific, professional, educational and awareness-building initiatives. The overarching mission is to raise the level of urological care in Europe, and for many years this has been done through educational and scientific programmes aimed at urologists. Today the EAU represents more than 15,000 medical professionals working in Europe and beyond its borders. To learn more about the EAU and its membership, visit www.uroweb.org.



Exhi

bitio

n

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)Via Luigi Taddei, 4, 6962 Viganello, SwitzerlandT: +41 (0)91 973 19 00F: +41 (0)91 973 19 02W: www.esmo.org

ESMO is the leading professional organisation for medical oncology. With more than 17,000 members representing oncology professionals from over 150 countries, ESMO is the society of reference for oncology education and information. ESMO’s educational resources support an integrated, multi-professional approach to cancer care. We have European roots and global reach: we welcome oncology professionals from around the world and we seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide.

EUROPEAN SOCIETY FOR RADIOTHERAPY & ONCOLOGY (ESTRO)Rue Martin V 40, 1200 Brussels, BelgiumT: +32 2775 93 40F: +32 2779 54 94W: www.estro.orgE: [email protected]

The European Society for Radiotherapy and Oncology, ESTRO, is a non-profit and scientific organisation that advances all aspects of radiation oncology in order to improve patients’ care in the multimodality treatment of cancer. With 6,500 members in and outside Europe, ESTRO supports all the radiation oncology professionals in their daily practice: radiation oncologists,

medical physicists, radiobiologists, RTTs (Radiation Therapists) and the wider oncology community. In order to achieve this, the Society promotes innovation, research and dissemination of science through its congresses, special meetings, educational courses and publications.

EXACT IMAGING 7676 Woodbine Avenue, Unit 15. Markham, ON Canada. L3R 2N2T: +1.905.415.0030 E: [email protected]: www.exactimaging.com

Exact Imaging’s ExactVu™ micro-ultrasound system for prostate imaging and targeted biopsy provides a 300% improvement in resolution over current standard-of-care ultrasound systems and superior resolution to MRI. Urologists can visualize suspicious regions and actually target (instead of blindly place) biopsies to those regions, aided by the PRI-MUS™ evidence-based micro-ultrasound protocol. For the minority of cases where MRI might assist (ie. prior negative biopsies), FusionVu™ is the forthcoming micro-US/MRI fusion application operating on the ExactVu micro-ultrasound platform.

INVIVO3545 SW 47th Avenue. Gainesville, FL 32608 USAT: +4407867908926E: [email protected]: www.invivocorp.com

Invivo is a business of Royal Philips and has nearly over a 20-year history as the pioneer of progressive MRI coils, advanced


Exhi

bitio

n


clinical visualization systems, and MRI-compatible interventional devices. Invivo is committed to providing technology solutions to keep pace with the needs of a growing healthcare market. Focusing on a better way for you and your patients, Invivo offers solutions that enable you to be more confident in your clinical practice.To learn more about Invivo solutions, visit www.invivocorp.com/

IPSEN PHARMA 65 quai Georges Gorse, 92100 BOULOGNE BILLANCOURT, Paris, FranceW: www.ipsen.com

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales close to €1.6 billion in 2016, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,100 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the

United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.

MDX HEALTHNovio Tech Campus, Transistorweg 5, 6534 AT NIJMEGEN, The NetherlandsT: +31 (0) 24 327 94 94W: mdxhealth.com

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

MSD CORPORATE HEADQUARTERS2000 Galloping Hill Road, Kenilworth, NJ 07033 U.S.A. T: 908-740-4000W: www.msd.com

For 125 years, MSD has been a global health care leader working to help the



Exhi

bitio

n

world be well. MSD is a tradename of Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd.com

NUCLEIX Ltd.3 Pekeris St. , Rehovot 7670230 ISRAELT: +972-8-916-1616F: +972-8-916-6966W: www.nucleix.comE: [email protected]

Nucleix develops, manufactures and markets highly innovative and non-invasive molecular cancer diagnostic tests. Our highly sensitive and specific tests are based on identification of subtle changes in methylation patterns in liquid biopsy samples (such as blood or urine). Nucleix’s technology is based on a combination of a new biochemical platform in conjunction with sophisticated bioinformatics techniques and algorithms, which allows it to develop biomarker panels with superior performance. Our first product Bladder EpiCheck® is a CE marked urine test for monitoring of bladder cancer that has shown superior sensitivity and specificity in several independent cohorts, performed at leading European centers.

SANDOZ INTERNATIONAL GMBH3 Pekeris St. , Rehovot 7670230 ISRAELT: +972-8-916-1616F: +972-8-916-6966W: www.nucleix.comE: [email protected]

Nucleix develops, manufactures and markets highly innovative and non-invasive molecular cancer diagnostic tests. Our highly sensitive and specific tests are based on identification of subtle changes in methylation patterns in liquid biopsy samples (such as blood or urine). Nucleix’s technology is based on a combination of a new biochemical platform in conjunction with sophisticated bioinformatics techniques and algorithms, which allows it to develop biomarker panels with superior performance. Our first product Bladder EpiCheck® is a CE marked urine test for monitoring of bladder cancer that has shown superior sensitivity and specificity in several independent cohorts, performed at leading European centers.

SANOFI GENZYME54, Rue La Boétie, 75008 Paris, FranceT: +33 (0)153 77 40 00W: www.sanofi.com

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that


Exhi

bitio

n

are often difficult to diagnose and treat, providing hope to patients and their families.

SYNERGO® BY MEDICAL ENTERPRISESA: Amsterdamseweg 147A, 1182GT

Amstelveen, The Netherlands T: +31 20 6423719E: [email protected]: www.medical-enterprises.com

Medical Enterprises Group develops innovative minimally invasive technologies providing benefits for both patients and healthcare systems. The lead product, Synergo® RITE (Radiofrequency Induced Thermo-chemotherapeutic Effect) offers the clinically effective, safe and easy way to deliver the tri-modality of RF radiation (local, non-ionising), chemotherapy (cooled, recirculated) and deep tissue hyperthermia (targeted at the tissue by the RF). Synergo® treatment reduces recurrences and the need for repetitive surgical interventions and reducing the necessity for cystectomy, radiotherapy and/or expensive systemic treatments. Thousands of patients in 10 countries have already been successfully treated and over 40 scientific publications, including RCTs, have been published, proving its safety and efficacy and even its RFS-superiority to BCG, the gold standard of over 40 years. Synergo® has become a common practice worldwide to treat intermediate and high-risk patients who, in many cases, failed previous treatments or have no other available alternatives. It is recommended as the only proven efficacious technology for NMIBC in the EAU 2017 guidelines.


The organisers respectfully acknowledge the following sponsors for providing unrestricted educational grants and services to the 9th European Multidisciplinary Meeting on Urological Cancers (EMUC17):

Silver Sponsors

Other Sponsors and Exhibitors

BLUE EARTH DIAGNOSTICSCOOK MEDICAL

C-TRUS ANA EXACT IMAGING

HITACHIINVIVO IPSEN

MDX HEALTHMSD

NUCLEIXSANDOZ INTERNATIONAL GMBH

SYNERGO BY MEDICAL ENTERPRISES

Acknowledgement Industry Partners

What science can do



Notes

We are committed to the fight against cancer and to making innovative treatments available that can extend and improve the lives of those suffering from cancer. To do this we focus our efforts in areas where we can develop best-in-class medicines, advancing treatments where there are real needs for patients. This has resulted in a number of treatments for various cancers moving through clinical development, with many more in early stage research.

At Astellas, we’re focused on making changing tomorrow a reality.

Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients worldwide.

astellas.eu

© October 2017 Astellas Pharma Europe Ltd. ONC/17/0025/APELa


Notes


SGZ_SIOG_Congress_Program_Book_ad.indd 1 9/26/2017 3:56:23 PM

www.emuc18.org

Abstract submission

deadline1 July 2018

8-11 November 2018Amsterdam, The Netherlands

10th European Multidisciplinary Congress on Urological CancersIn conjunction with the• 7th Meeting of the EAU Section of Urological Imaging (ESUI)• EMUC Symposium on Genitourinary Pathology and Molecular

Diagnostics (ESUP)• European School of Urology (ESU)• EAU Young Academic Urologists Meeting (YAU)

Implementing multidisciplinary strategies in genito-urinary cancers

Join us next year in Amsterdam!

Programme Book - European Association of...

Documents

Transcript of Programme Book - European Association of...